A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)

Treatment with abirterone acetate, in combination with prednisone, is beneficial for some patients with molecular apocrine tumours.

from Cancer via ola Kala on Inoreader http://ift.tt/1L7BpEd
via IFTTT